B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2

[Background]: The COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the need for vaccines targeting both neutralizing antibodies (NAbs) and long-lasting cross-reactive T cells covering multiple viral proteins to provide broad and durable protection against emerging variants.

Bibliographic Details
Authors: Perdiguero, Beatriz, Álvarez, Enrique, Marcos-Villar, Laura, Sin, Laura, López-Bravo, María, Valverde, José Ramón, Sorzano, Carlos Óscar S., Falqui, Michela, Coloma, Rocío, Esteban, Mariano, Guerra, Susana, Gómez, Carmen E.
Format: article
Status:Published version
Publication Date:2024
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:dnet:digitalcsic_::1ea846de5c9d82f36feee5a35eb7b30a
Online Access:http://hdl.handle.net/10261/370810
Access Level:Open access
Keyword:SARS-CoV-2
Vaccine
Multiepitopic protein
DNA and MVA vectors
Innate response
Cellular response
Immunogenicity
Efficacy in mice
ISG15 adjuvant
Description
Summary:[Background]: The COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the need for vaccines targeting both neutralizing antibodies (NAbs) and long-lasting cross-reactive T cells covering multiple viral proteins to provide broad and durable protection against emerging variants.

Similar Items